Key result
Autologous CD34+ cell therapy has shown potential safety and efficacy in various cardiovascular diseases, including acute myocardial infarction, heart failure, and refractory angina.
Why the study?
Autologous CD34+ cells have shown regenerative and angiogenic potential in ischaemia, prompting review of trials evaluating their safety and therapeutic potential across cardiovascular diseases.
Does autologous CD34+ stem/progenitor cell therapy improve outcomes in patients with cardiovascular disease?
Design
Review
Authors
Loading...
Supports expanded regenerative options in refractory CV disease; extends late-phase trial evidence across multiple indications.
Does autologous CD34+ stem/progenitor cell therapy improve outcomes in patients with cardiovascular disease?
Autologous CD34+ stem cell therapy shows promise as a safe and potentially effective regenerative treatment for refractory angina, acute myocardial infarction, and heart failure.
Prasad et al. (2020) conducted a review in Cardiovascular disease (refractory angina, acute myocardial infarction, heart failure). Autologous CD34+ stem/progenitor cell therapy was evaluated. Autologous CD34+ cell therapy has shown potential safety and efficacy in various cardiovascular diseases, including acute myocardial infarction, heart failure, and refractory angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: